Of four clinical studies that have verified the efficacy of letrozole in recurrent ovarian cancers [31-34], three clinical studies conducted in patients with ERα-positive recurrent ovarian cancers showed that the response rate to letrozole was 11.8% in the 102 patients [31-33]. Here, ESR1 is linked to ovarian carcinoma.